Lactobacillus Crispatus

Phase 2Small molecule

Lactobacillus Crispatus is one of 57 small molecule programs targeting Keratoconjunctivitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconjunctivitisActive, not recruiting

Spinal Cord InjuryActive, not recruiting

KeratoconjunctivitisPhase 2/Phase 3

Active, not recruiting

Spinal Cord InjuryPhase 2

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 3

3 2

Proamatine

Takeda

Phase 3

2 3

Minocin

TTriax

Phase 3

2 4

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 5

Cesamet

BBausch Health Americas, Inc.

Phase 3

1 6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 7

Genotropin

Myrbetriq

2 9

Gleevec

Novartis

Phase 2

1 10

Fampridine-SR

AAcorda Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

RCT

NCT05230511

Q1 2027

Phase 1Recruiting

Study completion

NCT07308808

Clinical

Trials by Indication[1]

RCT1 trial

Intravesical LGG VS Saline Bladder Wash RCT

Recruiting·MMedstar Health Research Institute·Phase 2·NCT05230511·120 enrolled

Spinal Cord Injury1 trial

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

Completed·MMedstar Health Research Institute·Phase 2·NCT02748317·96 enrolled

Veterans1 trial

Probiotic (LGG) for Veterans With PTSD

Completed·VVA Eastern Colorado Health Care System·Phase 2·NCT04150380·383 enrolled

Probiotics1 trial

Single Vs Multi-strain Probiotics for Preterm Neonates

Completed·MMadiha, MPhil·Phase 4·NCT07296718·249 enrolled

Keratoconjunctivitis1 trial

Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment

Completed·—·Phase 2/3·NCT00445120·48 enrolled

1 more indication

Unspecified1 trial

Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation

Recruiting·MMedstar Health Research Institute·Phase 1·NCT07308808·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Lactobacillus Crispatus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactobacillus Crispatus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactobacillus Crispatus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medstar Health Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedstar Health Research Institute

Lactobacillus Crispatus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

RCT1 trial

Spinal Cord Injury1 trial

Veterans1 trial

Probiotics1 trial

Keratoconjunctivitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News